Muscarinic Acetylcholine Receptor M1 (CHRM1) Antibody

Background

CHRM1 encodes the cholinergic receptor muscarinic 1, which is a member of the muscarinic acetylcholine receptor family. These receptors are G protein-coupled receptors (GPCRs) that mediate the actions of acetylcholine, a key neurotransmitter in the central nervous system (CNS) and peripheral tissues. CHRM1 is primarily expressed in the cerebral cortex, hippocampus, and basal ganglia, playing an essential role in cognitive processes such as learning, memory, and attention. Activation of CHRM1 leads to the stimulation of phospholipase C (PLC) via Gq/11 proteins, which increases intracellular calcium ion concentration and activates protein kinase C (PKC). Dysregulation of CHRM1 has been associated with neurological and psychiatric disorders, including Alzheimer's disease, schizophrenia, and epilepsy. Pharmacologically, CHRM1 agonists enhance cognitive function, while antagonists can alleviate conditions like muscle spasms and excessive salivation. CHRM1 remains a critical target in neurodegenerative research, as modulation of this receptor may restore acetylcholine signaling and improve cognitive decline.